Issue link: https://www.e-digitaleditions.com/i/1546950
Inhalation OctOber 2026 27 including mucus, surfactants, the respiratory epithe- lium, macrophages and immune cells [20]. Barr, et al. confirmed that phages adhere to the glycan res- idues of mucin, which can facilitate more encoun- ters with bacteria [20]. Overproduction of mucus in conditions like cystic fibrosis promotes the formation of bacterial aggregates called biofilms. As with anti- biotics, the diffusion of phages through biofilms may be difficult, which can limit their antibacterial activ- ity. Some phages are equipped with depolymerase enzymes that can aid the breakdown of biofilms [21]. Phages can also be uptaken by alveolar macrophages through phagocytic action. Studies show that phages can undergo non-specific interactions with epithelial cells, which can act as a sink in phage therapy. Once internalized into the epithelial cells, phages can survive for a few hours. is can be beneficial for targeting intracellular bacteria like Mycobacte- rium tuberculosis. Upon internalization, phages can also undergo intercellular degradation [22]. Cellular uptake by the lung epithelial cells may be unfavorable to extracellular bacteria like P. aeruginosa, which is primarily present outside the epithelium in the lung airways. Overall, uptake by non-target human cells can reduce the availability of phages to kill the target bacterium at the infection site. Phages can activate the toll-like receptors (TLR-9) present on epithelial cells, trigger the release of pro-inflammatory cyto- kines and elicit an immune response [23]. Figure 2 highlights several physiological barriers encountered by phages on inhalation. e pharmacokinetics of phages differs from conven- tional drugs. Several factors such as the location of target pathogen, its density, multiplicity of infection (phage-to-bacteria ratio), method and frequency of administration, contribute to their therapeutic effi- cacy [24]. Understanding of phage distribution in the lungs and pharmacokinetic behavior is still in its infancy. A recent study demonstrated intratracheal administration can achieve higher lung exposure (390-fold) and lower plasma exposure (490-fold), compared to intravenous administration [25]. Addi- tionally, the effect of phage self-replication should be taken into consideration for dosage regimen design. Formulation and aerosolization considerations e challenges in inhaled phage delivery (described above) suggest the need for developing formulations that offer improved phage protection. e overar- ching goal is to produce phage-based formulations with: (i) limited viability loss during manufactur- ing and storage, (ii) improved aerosol performance and (iii) effective targeting of the infection site in the lungs. e following section discusses formulation strategies and considerations for phage stabilization and aerosolization. 2026 ONLINE REFERENCE & BUYER'S RESOURCE NOW AVAILABLE This valuable resource from Inhalation provides a compilation of organizations, suppliers, products and services that support the research, development and manufacturing of inhaled pharmaceuticals. DON'T MISS IT, DOWNLOAD IT NOW. INHALATIONMAG.COM

